Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00040729 · ClinicalTrials.gov registry record

Genetic Study of Patients Previously Treated With Flavopiridol on Clinical Trial NCI-97-C-0171C

A clinical trial, sponsored by National Cancer Institute (NCI).

Completed
Registry status

NCT00040729: Completed study, sponsored by National Cancer Institute (NCI).

NCT00040729 is a clinical trial that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add start date to calendar (.ics) →

The verdict

NCT00040729 has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status

Study Summary

RATIONALE: Genetic testing for a specific enzyme may help doctors determine whether side effects from or response to chemotherapy are related to a person's genetic makeup. PURPOSE: Genetic trial to determine whether different forms of the UGT1A1 gene are related to the body's ability to break down drugs and to the gastrointestinal side effects seen in patients previously treated with flavopiridol.

Interventions

  • GENETIC mutation analysis

Trial Details

FieldValue
Start Date 2002-03
National Cancer Institute (NCI)

3,257 total trials

What the finished NCT00040729 record still lists

NCT00040729 is an observational study that tracks outcomes without assigning an intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 0 conditions, and to 1 intervention - of which mutation analysis is the first listed.

NCT00040729 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00040729 about?

NCT00040729 is a clinical study titled "Genetic Study of Patients Previously Treated With Flavopiridol on Clinical Trial NCI-97-C-0171C". RATIONALE: Genetic testing for a specific enzyme may help doctors determine whether side effects from or response to chemotherapy are related to a person's genetic makeup. PURPOSE: Genetic trial to determine whether different forms of the UGT1A1 gene are related to the body's ability to break down ...

What is the current status of trial NCT00040729?

This trial is currently completed. The study started on 2002-03.

What interventions are being tested in trial NCT00040729?

The interventions under investigation include: mutation analysis (GENETIC).

Who is sponsoring clinical trial NCT00040729?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00040729, the US trial registry maintained by the National Library of Medicine. NCT00040729 (unsized enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.